

RECORD OF TELEPHONE CONVERSATION

Submission Information

Application Type	BLA
STN	125428/0.0
Review Office	OVRR
Applicant	Dynavax Technologies Corporation / Lic. # 1883
Product	Hepatitis B Vaccine (Recombinant), Adjuvanted
Trans-BLA Group:	No

Telecon Details

Telecon Date/Time	18-AUG-2017 12:53 PM
Author	AGNIHOTHAM, SUDHAKAR
EDR	No
Post to Web	No
Outside Phone Number	
FDA Originated?	Yes
Communication Categories	AD - Advice
Related STNs	None
Related PMCs	None
Telecon Summary	Follow up Clarification to the telecon held on 8/15/17
FDA Participants	Sudhakar Agnihothram, Katherine Berkousen and Richard Daemer
Applicant Participants	Elaine Alambra, Senior Director Regulatory Affairs

Telecon Body:

From: Agnihothram, Sudhakar

Sent: Friday, August 18, 2017 12:35 PM

To: 'Elaine Alambra'

Cc: Berkousen, Katherine; Daemer, Richard J.

Subject: STN 125428/0 : Follow-up Clarification to the telecon held on 8/15/17

RECORD OF TELEPHONE CONVERSATION

Dear Elaine,

We would like to summarize the points we clarified during our telecon on Tuesday August 15, 2017. Please also find the list of FDA Participants on the telecon.

- Sudhakar Agnihothram, OVRD/DVRPA
- Richard Daemer, OVRD/DVRPA
- Marian Major, OVRD/DVP
- Wellington Sun, OVRD/DVRPA
- Steven Anderson, OBE
- Deepa Arya, OBE/DE
- Silvia PerezVilar, OBE/DE

Summary:

We did not find the synopsis of the revised Pharmacovigilance plan submitted on August 9, 2017 adequate to address the concerns raised during the VRBPAC meeting on July 28, 2017. Your revised Pharmacovigilance plan should address the following additional issues:

1. Please provide further information regarding how you plan to address the potential for selection bias, particularly with respect to patients choosing to get vaccinated at a different site that offers another hepatitis B vaccine, and physicians choosing to postpone vaccination or sending high-risk patients to another KP clinic.
2. Please provide further details on the “quasi”-cluster randomization method you propose.
3. Your synopsis does not indicate the number of clinics participating in the Kaiser Northern and Southern California systems. It is not clear how similar or dissimilar these clinics are, based on the patient population/at-risk patients and any other factors. Please respond.
4. Please provide recent historical data on vaccine uptake, demographics and co-morbidities by age group of adults, ages 18 years and older, who have been vaccinated with at least one dose of hepatitis B vaccine in KPNC and KPSC. Please clarify how you will ensure enrichment of particular age groups or at-risk groups?
5. Please provide information on the feasibility of earlier and more frequent interim analyses than those suggested in the synopsis. Please provide the proposed frequency of analysis and indicate if you have considered use of near-real time surveillance.
6. Please clarify the stopping rules. For example, provide information on the potential actions that will be taken should the proposed hazard ratio be met. During the call you mentioned the option of suspending distribution of your vaccine. Please provide further details.
7. Please provide details on your plans to apply propensity score methods and include your statistical analysis plan.

Please let us know if you have any further questions.

Thanks, Sudhakar

RECORD OF TELEPHONE CONVERSATION

Sudhakar Agnihothram B.Pharm, Ph.D,
Primary Reviewer/ Regulatory Project Manager,
Division of Vaccine Related Product Applications,
Office of Vaccines Research and Review,
Center For Biologics Evaluation and Research,
10903, New Hampshire Avenue,
BLDG 71, 3215 C,
Silver Spring, Maryland, 20993.
Email: Sudhakar.Agnihothram@fda.hhs.gov
Ph: 301-348-3056